1-5 of 5
Hind Al Azzawi
Close
Sort by
Journal Articles

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Jayastu Senapati, Emmanuel Huante Almanza, Tapan M. Kadia, Guillermo Montalban-Bravo, Stefan Faderl, Koji Sasaki, Nicholas Short, Naval Daver, Courtney D. DiNardo, Lucia Masarova, Alessandra Ferrajoli, Elias Jabbour, Gautam Borthakur, Hind Al Azzawi, Marina Konopleva, Guillermo Garcia-Manero, Michael Andreeff, Hagop Kantarjian, Farhad Ravandi, Yesid Alvarado
Journal: Blood
Blood (2022) 140 (Supplement 1): 9050–9053.
https://doi.org/10.1182/blood-2022-171011
Published: 2022
Journal Articles

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Daniel Rivera, Tapan M. Kadia, Guillermo Montalban-Bravo, Stefan Faderl, Koji Sasaki, Nicholas J. Short, Naval Daver, Courtney D. DiNardo, Lucia Masarova, Alessandra Ferrajoli, Elias J. Jabbour, Gautham Borthakur, Hind Al Azzawi, Marina Konopleva, Guillermo Garcia-Manero, Michael Andreeff, Hagop Kantarjian, Farhad Ravandi, Yesid Alvarado
Journal: Blood
Blood (2021) 138 (Supplement 1): 2323.
https://doi.org/10.1182/blood-2021-149840
Published: 2021
Journal Articles

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Jorge M. Ramos Perez, Tapan M. Kadia, MD, Guillermo Montalban-Bravo, MD, Stefan Faderl, MD, Koji Sasaki, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Lucia Masarova, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Gautham Borthakur, Hind Al Azzawi, Naveen Pemmaraju, MD, Marina Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Guillermo Garcia-Manero, MD, Michael Andreeff, MD PhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Yesid Alvarado, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–34.
https://doi.org/10.1182/blood-2020-142570
Published: 2020
Journal Articles

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Jorge M. Ramos Perez, Tapan M. Kadia, MD, Guillermo Montalban-Bravo, MD, Christopher B. Benton, MD, Stefan Faderl, Koji Sasaki, MD, Kiran Naqvi, MDMPH, Jorge E. Cortes, MD, Naval G. Daver, MD, Courtney D. DiNardo, MDMSc, Elias Jabbour, MD, Gautam M. Borthakur, MD, Hind Al Azzawi, Naveen Pemmaraju, MD, Marina Y Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Nitin Jain, MD, Maro Ohanian, DO, Guillermo Garcia-Manero, MD, Michael Andreeff, MD PhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Yesid Alvarado, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2642.
https://doi.org/10.1182/blood-2019-129137
Published: 2019
Journal Articles

Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS

Gautam M. Borthakur, MD, Tapan M. Kadia, MD, Hind Al Azzawi, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1379.
https://doi.org/10.1182/blood-2019-131348
Published: 2019